SHC | Ticker Profile - Titan Protect

SHC

Sotera Health Company

Healthcare · Diagnostics & Research · NMS

$15.62

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4.4B

Total market value of the company

Trailing P/E

37.90

Expensive — high growth expected

Forward P/E

14.64

Based on estimated future earnings — lower means cheaper

Rev Growth

+10.0%

Year-over-year revenue change

Profit Margin

9.9%

How much profit the company keeps from each dollar of revenue

ROE

22.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$19.50

+25% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 8 analysts covering this stock

About Sotera Health Company

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

https://soterahealth.com

Country: United States Employees: 3,000 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.659

Good returns relative to risk taken

Kelly Fraction

0.0441

Modest edge detected — smaller position warranted

Calmar Ratio

0.479

Drawdown risk outweighs the returns — higher risk profile

Annual Return

20.1%

Historical annualised return based on price data

Max Drawdown

-42.1%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

181

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.82

Significantly more volatile than the market

52W High

$19.85

21% below the year high

52W Low

$10.80

45% above the year low

Avg Volume

3,640,640

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

8.0%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.41

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

364.72

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.82

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.36

Like current ratio but excludes inventory — stricter test

Gross Margin

55.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

31.3%

Profit from core operations before interest and tax

Free Cash Flow

$145M

Positive — the business generates more cash than it spends

Revenue (TTM)

$1.2B

Total revenue over the last 12 months

Net Income

$118M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$24.00

Target Median

$19.50

Target Low

$16.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go